Stoke Therapeutics price target raised to $21 from $18 at Canaccord

Canaccord analyst Sumant Kulkarni raised the firm’s price target on Stoke Therapeutics to $21 from $18 and keeps a Buy rating on the shares. The firm noted they announced very promising Phase 1/2a data from two open-label Phase 1/2a and two open-label extension (OLE) studies of STK-001 for Dravet syndrome. The data takes their probability of approval to 33% from 25%.